Comparative Effectiveness of Botulinum Toxin Injections and Extracorporeal Shockwave Therapy for Post-Stroke Spasticity: A Systematic Review and Network Meta-Analysis

Po-Cheng Hsu, MD,a Ke-Vin Chang, MD, PhD,b,c,d,e,* Yi-Hsiang Chiu, MD,d Wei-Ting Wu, MD,c,d and Levent Özcakar, MDf

aDepartment of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital, Taipei, Taiwan
bSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
cDepartment of Physical Medicine and Rehabilitation, National Taiwan University Hospital, Bei-Hu Branch, Taipei, Taiwan
dDepartment of Physical Medicine and Rehabilitation, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
eCenter for Regional Anesthesia and Pain Medicine, Wang-Fang Hospital, Taipei Medical University, Taipei, Taiwan
fDepartment of Physical and Rehabilitation Medicine, Hacettepe University Medical School, Ankara, Turkey

Summary

Background The anti-spasticity efficacy of botulinum toxin (BoNT) injection has been well established for patients with chronic stroke; however, extracorporeal shock wave therapy (ESWT), i.e. focused shockwave (FSW) and radial shockwave (RSW), has recently been applied. We aimed to investigate the comparative effectiveness of BoNT vs. ESWT in the reduction of spasticity among stroke survivors.

Methods PubMed, EMBASE, MEDLINE and Cochrane CENTRAL were searched from the earliest record to September 2021 for randomized controlled trials. Weighted mean differences (WMDs) on the reduction of the Modified Ashworth Scale before or at the 6th post-treatment week (short-term) and between the 7th and 12th weeks (mid-term) after the intervention were calculated. Ranking probabilities of the WMD were simulated to determine which treatment had the potential to possess the best effectiveness. inplasy.com registration: INPLASY202170018.

Findings A total of 33 studies comprising 1,930 patients were enrolled. The network meta-analysis revealed that BoNT injections, FSW and RSW were better in spasticity reduction than the control treatment(s) at the short term, with WMDs of -0.69 (95% CI, -0.87 to -0.50), -0.36 (95% CI, -0.69 to -0.03) and -0.62 (95% CI, -0.84 to -0.40), respectively. Likewise, mid-term effects of BoNT injections, FSW and RSW also revealed superiority, with WMDs of -0.44 (95% CI, -0.62 to -0.26), -0.74 (95% CI, -1.26 to -0.23) and -0.79 (95% CI, -1.07 to -0.51), respectively. Ranking probability analysis revealed that RSW had the highest probability of being the best treatment for spasticity reduction at the short-term (62.2%) and mid-term (72.3%) periods during the follow up.

Interpretation BoNT injections and ESWT are effective in alleviating post-stroke spasticity at the mid-term. The effectiveness of ESWT was comparable to BoNT injections, and RSW had the potential to be the best treatment for spasticity reduction among the three treatment options. More prospective trials incorporating head-to-head comparisons of BoNT injections vs. ESWT are needed to validate the role of ESWT in reducing post-stroke spasticity.

Funding The current research project was supported by (1) National Taiwan University Hospital, Bei-Hu Branch; (2) Ministry of Science and Technology (MOST 106-2314-B-002-180-MY3 and 109-2314-B-002-114-MY3); 3) Taiwan Society of Ultrasound in Medicine.

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Keywords: chemodenervation; radial shockwave; focused shockwave; hemiplegia; hypertonia

Abbreviation: BoNT, botulinum toxin; RSW, radial shockwave; FSW, focused shockwave; WMD, weighted mean difference; CI, confidence interval; ESWT, extracorporeal shock wave therapy; MAS, modified Ashworth scale

*Corresponding author. Ke-Vin Chang, MD, PhD, Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital, Bei-Hu Branch and National Taiwan University College of Medicine, Taipei, Taiwan
E-mail address: kvchang011@gmail.com (K.-V. Chang).
Introduction

Hypertonia is a common muscle tone abnormality following stroke, while spasticity is one of the components that manifests as a velocity-dependent increase in muscle tone along with enhanced tendon jerks. An imbalance in supraspinal inhibitory and excitatory inputs at the spinal cord leads to spasticity, a hyper-excitable state of the stretch reflexes. Spasticity can occur at any time after stroke, with a prevalence ranging from 17% to 46%. While it also has positive effects during post-stroke recovery (e.g., by providing weight-bearing support during standing and ambulation), spasticity is a major cause of disability, and thus its management is crucial in post-stroke care.

Various approaches, including physical therapy, splinting, oral medications, chemical neurolysis, and surgical interventions, have been used in the management of spasticity. Oral anti-spasticity medications (e.g., baclofen, tizanidine or diazepam) reduce muscle tone by acting on the central nervous system, but they may cause systemic side effects such as lethargy or drowsiness. Chemodenervation (e.g., phenol block) carries the risk of sensory loss and dysesthesia over the injected limb. Injection of botulinum toxin (BoNT), a protein neurotoxin derived from Clostridium botulinum, has emerged as one of the most effective anti-spasticity therapies, owing to its selective inhibition of acetylcholine release at the neuromuscular junction. However, BoNT injections possess possible side effects of post-injection weakness if the dose is non-optimal, and can lead to the formation of neutralizing antibodies after repeated injections. Surgical interventions (e.g., selective peripheral neurotomy or intrathecal baclofen pump implantation) are usually reserved for those with severe spasticity after non-invasive treatment.

Extracorporeal shockwave therapy (ESWT), which includes focused shockwave (FSW) or radial shockwave (RSW) application, has recently been applied in the management of spasticity. FSW and RSW differ in their physical properties, depth of penetration, and mode of generation. FSW is driven by piezoelectric, electromagnetic, or electrohydraulic effects, generating a pressure surge within several nanoseconds with the energy concentrated at a focal point. RSW is generated pneumatically with a slow-growing pressure, and dissipates energy through the contacted skin to the deeper tissues. The relevant mechanisms underlying ESWT have been attributed to its rheological effects, namely the alterations in muscle elasticity and extensibility, and induced nitric oxide production to act on neuromuscular junctions and to modulate secretion of interleukin.

A recent meta-analysis reviewed 16 randomized controlled trials (RCTs) of stroke patients, and reported that ESWT was effective in reducing upper-limb spasticity for more than 12 weeks. Another meta-analysis demonstrated that the beneficial effects of ESWT in alleviating lower-limb spasticity could last for more than four weeks. Compared with BoNT injections, ESWT is a non-drug therapy and does not elicit neuromuscular denervation. However, the anti-spasticity effectiveness of ESWT may vary according to the different applied modes that have not been probed by any prior meta-analysis. Therefore, the aim of this network meta-analysis was to synthesize and compare the effectiveness of BoNT injections, RSW, and FSW in reducing spasticity in patients with chronic stroke.

Methods

The present network meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension guidelines for network meta-analysis (PRISMA-NMA), and was prospectively registered on inplasy.com (INPLASY202170018). The data used to support the findings of this research are available within the main article and its online supplementary files.
Search strategy
We searched four electronic databases (PubMed, EMBASE, MEDLINE and Cochrane CENTRAL) for relevant articles published from the earliest records up to September 2021. Other data sources such as the Cochrane Database of Systematic Reviews and Clinical-Trials.gov were also searched for eligible articles. Moreover, we manually screened the reference lists of the included articles for pertinent trials. The following PICO (i.e., Population/Patient, Intervention, Comparison, and Outcome) question guided the search strategy: “In patients with post-stroke spasticity, which kind of intervention among BoNT injections, RSW, and FSW, has a better effect in spasticity reduction when compared with others?” The following keywords were used: “stroke”, “cerebrovascular disease”, “cerebral infarction”, “intracerebral hemorrhage”, “hemiplegia”, “hemiparesis”, “spasticity”, “hypertonia”, “shock wave”, “shockwave therapy”, and “botulinum toxin” during the literature search without language limitations. The databases were investigated based on the following algorithm: 

[[Stroke OR cerebrovascular disease OR cerebral infarction OR intracerebral hemorrhage OR hemiplegia OR hemiparesis] and (spasticity OR hypertonia) and (shock wave OR shockwave therapy)] OR [(stroke OR cerebrovascular disease OR cerebral infarction OR intracerebral hemorrhage OR hemiplegia OR hemiparesis) and (spasticity OR hypertension) and (shock wave OR shockwave therapy)] OR [(stroke OR cerebrovascular disease OR cerebral infarction OR intracerebral hemorrhage OR hemiplegia OR hemiparesis) and (spasticity OR hypertonia) and botulinum toxin]].

The complete search strategy is presented in the Supplementary Method.

Study selection
The detailed inclusion criteria for the network meta-analysis were as follows: (1) patients with post-stroke spasticity; (2) RCTs including at least two therapeutic arms comprising BoNT, RSW, FSW, or a control group; and (3) the use of the Modified Ashworth Scale (MAS) for spasticity measurements. Studies were excluded if they (1) enrolled patients with etiologies other than stroke (e.g., traumatic brain injury, multiple sclerosis, or spinal cord injury), (2) used combinational therapy (such as BoNT plus ESWT) instead of single treatments, (3) used scales other than MAS for spasticity evaluation, or (4) were animal studies.

Data extraction and quality assessment
Two authors, who had similar expertise and experience in rehabilitation medicine (i.e. for more than 10 years), independently evaluated the eligible articles after removal of duplications. If the designated outcome variables were unavailable or incomplete in the published articles, we tried to contact the corresponding authors for the original data. The following information was extracted by both reviewers concurrently using the same form: the author(s), year, case number, patient demographics (average age, sex, and duration from onset), stroke type, details of applications of ESWT and BoNT, treatment sites, time frame of follow-up, and relevant outcomes. All the aforementioned information is summarized in Tables 1 and 2.

The methodological quality of the enrolled studies was assessed using the Cochrane Risk of Bias Tool for RCTs. The risk of bias was classified as high, low, or unclear. The quality assessment was based on the following aspects: selection bias (sequence generation and allocation concealment), performance (blinding of patients and personnel), detection (blinding of outcome assessment), attrition (incomplete outcome data), and reporting (selective outcome). Any discordance in reporting regarding article evaluation, data extraction, and risk of bias between the two assessors was resolved through discussion or by the judgment of a third author.

Data synthesis and analysis
The outcome was the weight mean difference (WMD) on MAS reduction in the short- and mid-term. The short- and mid-terms were defined as the periods before or at the 6th week post-treatment and between the 7th and 12th post-treatment weeks, respectively. Similar therapeutic arms in the same study (e.g., those comparing BoNT injections of different doses or ESWT of various sessions) were merged into a single group for analysis. The control treatments consisted of normal saline injection, sham ESWT, physical therapy, and oral anti-spastic medications. If there were several measurements within the same time frame (short- or mid-term), the outcome recorded at the last follow-up was chosen. In both time frames, we used a consistent strategy to extract our outcome variables. As a minimum of three weeks is needed for BoNT to take action,22 it would be better to extract data from the last follow-up point for better comparability with other active treatments. If the retrieved articles only reported the medians and interquartile range, the quantile estimation approach proposed by McGrath et al.22 was applied to estimate the mean and standard deviation.

For the pairwise meta-analysis, the random-effects model was used for data pooling. The Cochrane Q tests and I² statistic were employed to determine the heterogeneity of direct comparisons, and significant heterogeneity was assumed in the case of an I² value >50%. A mixed treatment comparison with a generalized linear mixed model was used for the network meta-analysis, enabling the indirect estimation of the differences between treatments A and B through their comparisons with treatment C. The existence of inconsistencies between the direct and indirect comparisons was examined using the loop inconsistency model. Probability ranking metrics were used to reflect clinically important relative differences in the outcomes which were shown on the ranking probability curves and the surface under
| Author, year | Blinding | Allocation concealment | Inclusion criteria | Intervention arm | Case number (Male/Female) | Age (year) | Stroke type (ischemic/hemorrhagic/embolic) | Post-stroke follow-up (months) |
|-------------|----------|-----------------------|-------------------|-----------------|---------------------------|-----------|--------------------------------|--------------------------------|
| Bae et al. 2010 | Not mentioned | Not mentioned | Aged 18-80 years; Onset of stroke >12 months; MAS ≥ 2 | FSW | 23 (15/8) | 56.7±12.4 | 13/10/0 | 22.0±8.2 |
| | | | | Control | 9 (5/4) | 53.4±16.8 | 3/6/0 | 25.1±14.6 |
| Fouda et al. 2015 | Not mentioned | Not mentioned | Onset of stroke >3 months; MAS ≥ 2 | RSW | 15 (15/0) | 52.7±5.9 | 6/9/0 | 14.6±9.2 |
| | | | | Control | 15 (15/0) | 51.8±6.8 | 5/10/0 | 12.2±8.1 |
| Tirbisch et al. 2015 | Single-blinded (assessors) | Yes | Onset of stroke 3 weeks and 6 months; MAS > 2 | RSW | 4 (1/3) | 49.5±8.7 | 3/1/0 | 4.0±0.8 |
| | | | | Control | 4 (2/2) | 61.3±11.1 | 3/1/0 | 3.4±1.6 |
| Dymarek et al. 2016 | Single-blinded (patients) | Not mentioned | Aged 18-80 years; Onset of stroke >9 months and 10 years; MAS ≥1 | RSW | 30 (19/11) | 61.4±12.7 | 30/0/0 | 51.3±25.5 |
| | | | | Control | 30 (15/15) | 60.9±9.5 | 30/0/0 | 51.5±26.1 |
| Kim et al. 2016 | Double-blinded (patients and assessors) | Not mentioned | Onset of stroke >3 months; Hemiplegic and limited ROM of shoulder | RSW | 17 (7/10) | 65.9±8.3 | 8/9/0 | 28.8±33.3 |
| | | | | Control | 17 (10/7) | 66.1±15.8 | 5/12/0 | 22.2±18.3 |
| Li et al. 2016 | Single-blinded (assessors) | Not mentioned | Onset of stroke >9 months; MAS ≥ 2 | RSW – 1 session | 20 (15/5) | 56.8±13.4 | 10/10/0 | 66.7±42.8 |
| | | | | RSW – 3 sessions | 20 (12/8) | 55.4±13.6 | 10/10/0 | 61.7±43.5 |
| Duan et al. 2017 | Single-blinded (assessors) | Not mentioned | Onset of stroke < 3 months; MAS between 1-3 | RSW | 24 (13/11) | 50.6±8.6 | 7/17/0 | 1.6±0.4 |
| | | | | Control | 24 (12/12) | 51.9±9.4 | 9/15/0 | 1.7±0.5 |
| Taheri et al. 2017 | Not mentioned | Yes | Aged 17-70 years; onset of stroke >1 month; ability to walk for 10 meters; MAS ≥ 2 | FSW | 13 (9/4) | 56.5±11.6 | 11/2/0 | 33±21.4 |
| | | | | Control | 12 (8/4) | 54.9±9.4 | 11/1/0 | 25.8±9.9 |
| Yoon et al. 2017 | Not mentioned | Not mentioned | Onset of stroke >6 months; MAS ≥ 2 | FSW-Elbow belly | 26 (26/0) | 58.7±15.7 | NR | 100.3±98.3 |
| | | | | FSW-Elbow junction | 28 (27/1) | 63.1±11.8 | NR | 66.8±51.9 |
| | | | | Control-Elbow | 26 (23/3) | 64.4±13.8 | NR | 63.5±94.1 |
| | | | | FSW-Knee belly | 13 (13/0) | 61.0±2.2 | NR | 99.1±85.1 |
| | | | | FSW-Knee junction | 13 (13/0) | 66.9±4.9 | NR | 51.1±36.0 |
| | | | | Control-Knee | 18 (16/2) | 59.5±16.9 | NR | 38.7±30.2 |
| Xu et al. 2018 | Not mentioned | Not mentioned | Onset of stroke between 2 weeks and 3 months; MAS between 1-3; simplified FMA < 50; MBI < 60 | RSW | 28 (17/11) | 52.8±12.0 | 14/14/0 | 52.9±13.2 |
| | | | | Control | 28 (18/10) | 54.2±12.4 | 15/13/0 | 53.6±12.5 |
| Wu et al. 2018 (EJPRM) | Double-blinded (patients and assessors) | Yes | Aged ≥ 18 years; onset of stroke >6 months; MAS >1; able to walk +/- orthosis | FSW | 15 (9/6) | 60.3±9.9 | 10/5/0 | 53.2±26.7 |
| | | | | RSW | 16 (9/7) | 59.6±11.3 | 10/6/0 | 55.7±26.1 |
| Guo et al. 2019* | Single- blinded (assessors) | Not mentioned | Onset of stroke >6 months; MAS <4 | RSW | 30 (16/14) | 66.8±11.0 | 12/18/0 | 3.2±4.5 |
| | | | | Control | 30 (16/14) | 69.7±11.1 | 13/17/0 | 3.5±5.1 |
| Lee et al. 2019 | Double-blinded (patients and assessors) | Not mentioned | Aged 30-70 years; onset of stroke >6 months; MAS > 1 | FSW | 9 (7/2) | 50.9±8.8 | 4/5/0 | 12.9±9.0 |
| | | | | Control | 9 (9/0) | 44.1±4.1 | 2/7/0 | 10.4±9.1 |
| Author, year | Blinding | Allocation concealment | Inclusion criteria | Intervention arm | Case number (Male/Female) | Age (year) | Stroke type (ischemic/hemorrhagic/embolic) | Post-stroke follow-up (months) |
|-------------|----------|------------------------|-------------------|-----------------|----------------------------|-----------|--------------------------------|--------------------------------|
| Tabra et al. 2021 | Double-blinded (assessors, lack of details regarding patients) | Yes | Onset of stroke > 1 year; MAS > 1 | RSW | 20 (18/2) | 55.7 ± 9.3 | 13/7/0 | 33.5 ± 5.6 |
| | | | | Control | 20 (17/3) | 53.9 ± 10.2 | 11/9/0 | 31.7 ± 9.2 |
| Aslan et al. 2021 | Double-blinded (patients and assessors) | Yes | Aged 20-80 years; MAS > 1 | RSW | 17 (9/8) | 57.5 ± 14.3 | NR | 35.5 ± 70.2 |
| | | | | Control | 16 (9/7) | 58.8 ± 10.8 | NR | 28.9 ± 76.5 |
| Wu et al. 2018 (APMR) | Single-blinded (assessors) | Yes | Aged > 20 years; onset of stroke > 6 months; MAS > 1 | RSW | 21 (13/8) | 60.0±11.1 | 11/9/0 | 38.8±5.9 |
| Hesse et al. 1998 * | Double-blinded (patients and assessors) | Not-mentioned | Onset of stroke between 6-12 months; upper limb flexor spasticity MAS ≥ 3 and nonfunctional | BoNT / Control | 24 (12/12) | 52.3 (32-73) | 18/6 | 7.45 (6-11) |
| Bakheit et al. 2000 | Double-blinded (patients and assessors) | Not-mentioned | Onset of stroke > 3 months; MAS ≥ 2 in wrist, elbow, and finger flexors | BoNT | 63 (39/24) | 62.2±13.0 | 36/12/10 (5 unknown) | NR |
| | | | | Control | 19 (12/7) | 63.6±14.1 | 8/3/4 (4 unknown) | NR |
| Bhakta et al. 2000 | Double-blinded (patients and assessors) | Yes | MAS > 2 of finger flexor or elbow flexor; at least moderate difficulty with 2 out of 8 items defining patient disability | BoNT | 20 (13/7) | 60.2 (22.6–77.6) | 15/5 | 37.2 (9.6–398.6) |
| | | | | Control | 20 (10/10) | 53.8 (11.2–72.8) | 15/5 | 32.4 (6–180) |
| Bakheit et al. 2001 | Double-blinded (patients and assessors) | Not-mentioned | Onset of stroke >3 months; MAS ≥ 2 in at least 2 out of the elbow, wrist and finger flexors and > 1 in the remaining area | BoNT | 27 (11/16) | 67.0±11.1 | 14/8/2 (3 unknown) | NR |
| | | | | Control | 32 (15/17) | 64.1±13.2 | 15/3/11 (3 unknown) | NR |
| Childers et al. 2004 | Double-blinded (patients and assessors) | Yes | Aged 21-80 years; body weight > 60 Kg; onset of stroke > 6 weeks; wrist flexor MAS ≥ 3 and elbow flexor MAS ≥ 2 | BoNT- low dose | 21 (16/5) | 59.3(30.4-76.1) | 51/19/16 (5 unknown) | 28.7 (0.9-108.5) |
| | | | | BoNT- middle dose | 23 (15/8) | 61.1(39.6-79.4) | unknown | 31.2 (1.2-226.9) |
| | | | | BoNT- highest dose | 21 (17/4) | 59.0(35.4-77.7) | unknown | 16.5 (2.6-99.2) |
| | | | | Control | 26 (13/13) | 60.6(33.8-76.0) | 26.6 (2.1-211.7) | NR |
| Jahangir et al. 2007 | Double-blinded (Lack of detail) | Not-mentioned | Aged ≥ 21 years; stroke onset > 1 year; spasticity > 3 months and wrist and fingers MAS ≥ 2 | BoNT | 27 (18/9) | 60.48±11.6 | 27/0/0 | 49.70±35.5 |
| | | | | Control | 25 (15/10) | 61.08±10.9 | 22/3/0 | 40.36±44.5 |
| Marco et al. 2007 | Double-blinded (patients and assessors) | Yes | Aged ≥ 18 years; onset of stroke > 3 months; MAS ≥ 3; moderate-severe spastic shoulder pain | BoNT | 14 (10/4) | 63.9±10.6 | 14/0/0 | 5.8 (2.9-8.8) |
| | | | | Control | 15 (11/4) | 67.2±7.4 | 15/0/0 | 4.4 (3.7-7) |
| McCrory et al. 2009 | Double-blinded (patients and assessors) | Yes | Aged ≥ 18 years; onset of stroke > 6 months; MAS ≥ 2 in at least 2 out of 3 of wrist, elbow and finger, and ≥ 1+ for the third area | BoNT | 54 (32/22) | 59.7±12.2 | NR | 63.6±104.4 |
| | | | | Control | 42 (26/16) | 58.4±14.6 | NR | 79.2±151.2 |

(continued on next page)
| Author, year       | Blinding                                       | Allocation concealment | Inclusion criteria                                                                 | Intervention arm | Case number (Male/Female) | Age (year) | Stroke type (ischemic/ hemorrhagic/ embolic) | Post-stroke follow-up (months) |
|-------------------|------------------------------------------------|------------------------|------------------------------------------------------------------------------------|-----------------|----------------------------|------------|---------------------------------------------|-------------------------------|
| Kaji et al. 2010  | Double-blinded (patients and assessors)       | Yes                    | Aged 20-80 years; body weight ≥ 50 Kg; onset of stroke ≥ 6 months; ankle flexor MAS>3 | BoNT            | 58 (50/8)                  | 62.4±8.7   | NR                                          | 80.8±72.8                     |
|                   |                                                |                        |                                                                                   | Control         | 62 (46/16)                 | 62.5±9.3   | NR                                          | 72.0±30.3                     |
| Kaji et al. 2010  | Double-blinded (patients and assessors)       | Yes                    | Aged 20-80 years; body weight ≥ 40 Kg; onset of stroke ≥ 6 months; wrist flexor MAS 3 or 4 and finger flexor MAS ≥ 2; or 3 on the DAS for at least one of 4 areas of functional disability | BoNT-low dose   | 51 (36/15)                 | 63.5±9.3   | NR                                          | 82.2±83.5                     |
|                   |                                                |                        |                                                                                   | BoNT-high dose  | 21 (19/2)                  | 62.7±9.7   | NR                                          | 91.3±63.4                     |
|                   |                                                |                        |                                                                                   | Control         | 37 (19/18)                 | 63.2±10.6  | NR                                          | 79.2±61.8                     |
| Shaw et al. 2011  | Single-blinded (assessor)                     | Yes                    | Aged < 80 years; onset of stroke > 4-6 weeks; 0:MAS=2 of finger and/or wrist flexors; Barthel index > 25 and FMA motor score < 20 | BoNT            | 9 (3/6)                    | 57±11      | 6/3/0                                        | 1.5±0.3                       |
|                   |                                                |                        |                                                                                   | Control         | 9 (3/6)                    | 66±11      | 7/2/0                                        | 1.4±0.3                       |
| Hesse et al. 2011 | Single-blinded (assessor)                     | Not-mentioned          | Aged ≥ 18 years; body weight ≥ 88 lbs, pain VAS ≥ 4; upper limb MAS ≥ 3            | BoNT            | 10 (6/4)                   | 60.2±7.8   | NR                                          | NR                            |
|                   |                                                |                        |                                                                                   | Control         | 11 (7/4)                   | 59.8±10.3  | NR                                          | NR                            |
| Wolf et al. 2012  | Double-blinded (patients and assessors)       | Not-mentioned          | Onset of stroke 3-24 months; volitional activation of wrist and finger muscles      | BoNT            | 12 (5/7)                   | 48.8±15.6  | NR                                          | NR                            |
|                   |                                                |                        |                                                                                   | Control         | 13 (5/8)                   | 49.8±13.7  | NR                                          | NR                            |
| Prazeres et al. 2016| Double-blinded (patients and assessors)      | Yes                    | Aged < 80 years; onset of stroke > 2-12 weeks; MAS ≥ 2 in primary targeted muscle group of upper limbs | BoNT            | 20 (12/8)                  | 52.5±11.0  | 16/4/0                                       | 34.2±21.4                     |
|                   |                                                |                        |                                                                                   | Control         | 20 (12/8)                  | 52.1±12.5  | 19/1/0                                       | 32.1±14.9                     |
| Rosales et al. 2018| Double-blinded (Lack of detail)              | Not-mentioned          | Stroke onset > 1 year; MAS ≥ 2                                                    | BoNT            | 28 (23/5)                  | 61.5±13.2  | 20/8/0                                       | 1.5±0.7                       |
|                   |                                                |                        |                                                                                   | Control         | 14 (10/4)                  | 56.5±9.7   | 10/4/0                                       | 1.6±0.6                       |
| Kerzoncuf et al. 2020| Double-blinded (patients and assessors)   | Yes                    | Stroke onset > 1 year; MAS ≥ 2                                                      | BoNT            | 23 (12/11)                 | 53.4±14.8  | 10/13/0                                      | 50.0±28.7                     |
|                   |                                                |                        |                                                                                   | Control         | 26 (12/14)                 | 50.7±12.9  | 14/12/0                                      | 71.0±67.1                     |

**Table 1:** Summary of the retrieved trials for treatment of post-stroke spasticity

Data format: Presented as mean ± standard deviation, except 1 indicates mean (minimum value to maximum value). 2 indicates median (minimum value to maximum value) and 3 indicates median (25 percentile value to 75 percentile value).

Abbreviations: ARAT, Action Research Arm Test; APMR, Archives of Physical Medicine and Rehabilitation; BoNT, botulinum toxin; CMRO, Current Medical Research and Opinion; EJPRM, European Journal of Physical and Rehabilitation Medicine; FMA: Fugl-Meyer Assessment; FSW, focused shockwave; MAS, modified Ashworth scale; MBI, modified Barthel index; NR, not recorded; ROM, range of motion; RSW, radial shockwave; VAS, visual analog scale.

* The study contains four study arms, and two of them were selected into meta-analysis after exclusion of the arms combining treatment other than ESWT and BoNT.
| Author, year | Intervention arm | Intervention detail | Guidance | Evaluating joint/muscle | Outcome measurement | Follow-up |
|------------|-----------------|---------------------|----------|------------------------|--------------------|-----------|
| Bae et al. 2010 FSW | ESWT (1200 shots, 0.12mJ/mm², 4 Hz to biceps brachii; once per week for 3 weeks) + physiotherapy | Ultrasound | Upper limb (biceps brachii) | MAS, modified Tardieu scale and modified Barthel index | Immediate after 1st session and before 2nd session, 1 week after last session |
| Control | Physiotherapy | N/A |
| Fouda et al. 2015 RSW | ESWT (1500 shots, 2.5 bar for forearm flexor muscles; 3200 shots, 2.5 bar for palmar interosseous muscles; once per week for 5 weeks) + physiotherapy | Landmark | Upper limb (wrist, finger) | MAS, pROM, VAS | Immediate |
| Control | sham RSW + physiotherapy | Landmark |
| Tirbisch et al. 2015 RSW | ESWT (2000 shots, 0.03mJ/mm², 10 Hz; 3 times per week for 3 weeks) + physiotherapy | Landmark | Lower limb (soleus and gastrocnemius) | MAS, modified Tardieu scale, ROM | Immediate |
| Control | Physiotherapy | N/A |
| Dymarek et al. 2016 RSW | ESWT (1500 shots, 0.030mJ/mm², 1.5 bar, 5Hz to FCR and FCU; single session) | Landmark | Upper limb (elbow, wrist, finger) | MAS*, bioelectrical activity, temperature distribution | Immediate, 1 and 24 hours |
| Control | Sham ESWT | N/A |
| Kim et al. 2016 RSW | ESWT (3000 shots, 0.39-1.95mJ/mm², 3-5.0 bar, 12Hz to greater and lesser tuberousities of the humeral head; 4 times per week for 2 weeks) | Ultrasound | Upper limb (supraspinatus and subscapularis) | VAS*, CMS, MAS, ROM, FMA | 1, 2 and 4 weeks |
| Control | Sham RSW | Ultrasonography |
| Li et al. 2016 RSW | ESWT (1500 shots, 3.5 bar, 5Hz for FCU, FCR; 4000 shots, 3.5bar, 5 Hz for intrinsic muscles and flexor digitorum tendon; once per week for 3 weeks (n=20), Single session (n=20)) | Ultrasonography | Upper limb (Wrist and hand) | MAS*, FMA | Immediate, 1, 4, 8, 12 and 16 weeks |
| Control | Sham RSW | Ultrasonography |
| Duan et al. 2017 RSW | ESWT (1500 shots, 3.0bar, 8Hz to biceps brachii; 3 times per week for 2 weeks) + physiotherapy | Landmark | Upper limb (biceps brachii) | MAS, FMA | Immediate |
| Control | Physiotherapy | N/A |
| Taheri et al. 2017 FSW | ESWT (1500 shots, 0.1 mL/mm², 4Hz to gastrocnemius muscle; once per week for 3 weeks) + Stretching exercise + oral anti-spastic medications | Landmark | Lower limb (ankle plantar flexor) | MAS, VAS, ROM, Clonus score, 3-m walk duration, and lower extremity functional score | 1, 3 and 12 weeks |
| Control | Stretching exercise + oral anti-spastic medications | N/A |
| Yoon et al. 2017 FSW | ESWT (1500 shots, 0.068–0.093 mL/mm², 15Hz to muscle belly or myotendinous junction of biceps brachii/semitendinosus; once per week for 3 weeks) + physiotherapy | Ultrasonography | Upper limb (elbow flexor) and lower limb (knee flexor) | MAS, modified Tardieu scale | Immediate after each treatment session |
| Control | Physiotherapy | N/A |
| Xu et al. 2018 RSW | ESWT (2000 shots, 2.0-3.0 bar, 8Hz to biceps brachii; once per week for 4 weeks) + physiotherapy | Landmark | Upper limb (biceps brachii) | MAS, FMA, modified Barthel index | 2 and 4 weeks |
| Control | Sham ESWT + physiotherapy | Landmark |

(continued on next page)
| Author, year | Intervention arm | Intervention detail | Guidance | Evaluating joint/muscle | Outcome measurement | Follow-up |
|-------------|-----------------|---------------------|----------|------------------------|---------------------|-----------|
| Wu et al. 2018 (EJPRM) | FSW | ESWT (3000 shots, 0.10 mJ/mm², 5 Hz to gastrocnemius and soleus muscles; once per week for 3 weeks) + physiotherapy | Landmark | Lower limb (gastrocnemius) | MAS*, Tardieu angles, ankle PROM, dynamic foot plantar contact area, gait speed | 1, 4 and 8 weeks |
| | RSW | ESWT (3000 shots, 2.0 bar, 5Hz, once per week for 3 weeks to gastrocnemius and soleus muscles) + physiotherapy | Landmark | | | |
| Guo et al 2019 | RSW | ESWT (2000 shots, 2.0-3.0 bar, 8 Hz to the intrinsic muscles and flexor digitorum tendon of the hand; 5 times per week for 4 weeks) + physiotherapy | Ultrasound | Upper limb (lack of detailed information) | MAS, FMA | 1, 3 and 6 months |
| | Control | Physiotherapy | N/A | | | |
| Lee et al. 2019 | FSW | ESWT (2000 shots, 0.1mJ/mm², 4Hz to gastrocnemius; single session) + physiotherapy | Ultrasound | Lower limb (ankle plantar flexor) | MAS, FMA, ROM | 30 minutes, 1 and 4 weeks |
| | Control | Sham ESWT + physiotherapy | Ultrasound | | MAS, FMA, Motricity Index, H/M ratio of FCR | 2 weeks and 3 months |
| Tabra et al. 2021 | RSW | ESWT (2000-3000 shots, 0.25-0.84 mJ/mm² with pressure 2.8 bar, 15 Hz to FCU, FCR, flexor digitorum and intrinsic hand muscles; once per week for 3 weeks) + physiotherapy | Landmark | Upper limb (wrist and hand) | MAS, FMA, Treatmen response rate | |
| | Control | Physiotherapy | N/A | Lower limb (ankle plantar flexor muscles) | MAS, Tardieu Scale, ankle ROM, 6-meter times walk test, modified Barthel index, strain index | 2 and 6 weeks |
| Wu et al. 2018 (APMR) | RSW | ESWT (1500 shots, 2 bar, 10 Hz to gastrocnemius muscle; twice per week for 2 weeks) + physiotherapy | Landmark | Upper limb (elbow flexor and wrist flexor) | MAS, Tardieu angle, pROM, FMA, treatment response rate | 1, 4 and 8 weeks |
| | Control | Sham ESWT + physiotherapy | EMG | Upper limb (elbow, wrist, finger) | MAS*, limb position at rest, ORS | 2, 6 and 12 weeks |
| Hesse et al. 1998 | BoNT | BoNT-A (Dysport®): 100-200 U FCR, 100-150 U FCU, 200-300U biceps brachii + physiotherapy | EMG | Upper limb (elbow, wrist, finger) | MAS*, limb position at rest, ORS | 2, 6 and 12 weeks |
| Bakheit et al. 2000 | BoNT | BoNT-A (Dysport®): 500 U: biceps brachii 200U, FDP 75, FDS 75, FCR 75, FDP 150, FDS 150, FCR 150 - 1000 U: biceps brachii 400U, FDP 150, FDS 150, FCR 150 - 1500 U: biceps brachii 600U, FDP 225, FDS 225, FCR 225 | EMG | Upper limb (elbow, wrist, finger) | MAS*, pROM, pain, Rivermead motor assessment, Barthel index, ORS | 2, 4, 8, 12 and 16 weeks |
| Control | Placebo | Landmark | Landmark | | | |

(continued on next page)
| Author, year | Intervention arm | Intervention detail | Guidance | Evaluating joint/muscle | Outcome measurement | Follow-up |
|-------------|------------------|---------------------|----------|-------------------------|---------------------|-----------|
| Bhakta et al. 2000 | BoNT | BoNT-A (Dysport®) 1000U: biceps brachii, brachioradialis, FDS, FDP, FCU | Landmark | Upper limb (elbow, finger) | Disability Scale *, CBS*, MRC, MVG, MAS, PROM, aROM, total pain score of paretic limb | 1, 2, 6 and 12 weeks |
| Bakheit et al. 2001 | Control | Placebo | Landmark | Upper limb (elbow, wrist, finger) | MAS*, aROM, PROM, pain, Barthel index, goal attainment scale, ORS | 4, 8, 12 and 16 weeks |
| Childers et al. 2004 | Control | BoNT-A (Botox®) | Upper limb (elbow, finger) | MAS*, Disability Scale, pain, FIM, SF-36, Global assessment of response to treatment | 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24 weeks |
| Childers et al. 2004 | Control | EMG | Upper limb (elbow, finger) | MAS*, Disability Scale, pain, FIM, SF-36, Global assessment of response to treatment | 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24 weeks |
| Jahan et al. 2007 | Control | Placebo | NR | Upper limb (wrist and finger) | MAS, Barthel index, EQ-5D | 1 and 3 months |
| Marco et al. 2007 | Control | EMG | Upper limb (shoulder) | Pain*, MAS, PROM | 1 week, 1, 3 and 6 months |
| McCrory et al. 2009 | Control | EMG | Upper limb (elbow, wrist and finger joints) | AQLQ, Pain, Hospital Anxiety and Depression Rating Scale, Goal Attainment Scaling, MAS Modified Motor Assessment Scale, Carer Burden scale, Patient disability scale, Global Assessment of Benefit | 8, 12, 20, and 24 weeks |
| Kaji et al. 2010 (J Neurol) | Control | Placebo | EMG | Lower limb (ankle) | MAS*, Gait pattern scale, gait speed, clinical global impression | 1, 4, 6, 8 and 12 weeks |

(continued on next page)
| Author, year | Intervention arm | Intervention detail | Guidance | Evaluating joint/muscle | Outcome measurement | Follow-up |
|-------------|------------------|---------------------|----------|-------------------------|---------------------|-----------|
| Kaji et al. 2010 (CMRO) | BoNT | BoNT-A (Botox®) | EMG | Upper limb (wrist, finger, thumb) | MAS*, disability assessment scale, clinical global impression | 1, 4, 6, 8 and 12 weeks |
| | Control | Placebo | EMG | Upper limb (elbow) | Action Research Arm Test *, MAS, Motricity Index, MVG, Nine Hole Peg Test, ORS, Barthel index, pain | 1, 3 and 12 months |
| Shaw et al. 2011 | BoNT | BoNT-A (Dysport®) median dose 200 units (range 100–300 U) + physiotherapy | NR | Upper limb (elbow) | Action Research Arm Test *, MAS, Motricity Index, MVG, Nine Hole Peg Test, ORS, Barthel index, pain | 1, 3 and 12 months |
| Hesse et al. 2011 | BoNT | BoNT-A (Xeomin®) 150 MU to the deep, superficial finger and wrist flexors + physiotherapy | Ultrasound | Fingers flexors II–V | MAS*, REPAS, FMA motor score, Disability Scale | 1 and 6 months |
| Marciniak et al. 2012 | BoNT | BoNT-A (Botox®) mean 188 U (range 140-200 U): 100-150 U pectoralis major +/- 40-60 U teres major | EMG | Upper limb (shoulder) | VAS*, MAS, disability assessment scale, FMA, ROM, McGill Pain Questionnaire short Form, FIM (hygiene) | 2, 4 and 12 weeks |
| Wolf et al. 2012 | BoNT | BoNT-A (Botox®) max dose 300 U over wrist and finger muscles + physiotherapy | EMG | Upper limb (wrist) | Wolf Motor Function Test*, Stroke Impact Scale, MAS, aROM | 1, 2 and 3 months |
| Prazeres et al. 2018 | BoNT | BoNT-A (Dysport®): lack of detail information | NR | Upper limb (wrist, elbow) | Time up and go test*, 6 minute walking test *, FMA*, MAS | 3, 6 and 9 months |
| Rosales et al. 2018 | BoNT | BoNT-A (Dysport®): 500U in targeted muscle of upper limb | NR | Upper limb | Time to re-injection, MAS, motor recovery score, Global assessment | 4, 6, 8, 10 and 12 weeks |
| Control | Placebo | NR | NR | NR | NR | NR |

(continued on next page)
the cumulative ranking area (SUCRA). The SUCRA value ranged between 0 and 1, and the treatments with a higher SUCRA value suggested better effectiveness and superior ranking. It was presented as the percentage of the mean rank of each treatment in relation to the presumed best intervention.

Publication bias was examined using Egger’s regression test and by inspection of the distribution pattern of the effect size on the funnel plot. All analyses were performed using the statistical software package Stata (StataCorp. 2015, Stata Statistical Software: Release 14, StataCorp LP, College Station, TX, USA). Statistical significance was set at \( p < 0.05 \).

Role of the funding source
The funders had no direct role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The corresponding author had full access to the data in the study, and had final responsibility for the decision to submit for publication.

Results

Study selection and subject characteristics
A primary search of the databases yielded 3,785 related studies. After excluding 1,679 duplicate and 2,037 non-relevant studies, 69 articles were deemed eligible. A total of 36 studies were further discarded because 11 of them lacked retrievable MAS data, six studies enrolled non-stroke participants, three studies were secondary analysis of published trials, 13 studies used scales other than the MAS for spasticity measurements, and three studies compared therapeutic arms other than the inclusion criteria (Supplementary Table 1). The remaining 33 studies were included in the final meta-analysis (Fig. 1).

Of the 33 included studies, 10 compared RSW with a control treatment, 26-30,32-35,37-39 four compared FSW with a control treatment, 35,37,38 one study compared FSW and RSW, 16 and 17 studies compared BoNT- \( ^{-} \) and 16 and 17 studies compared BoNT-A with a control treatment. 40-56 A total of 1,930 participants (1,277 men and 653 women) were enrolled in the meta-analysis. The mean age across the trials ranged from 44.1 to 69.7 years. The mean duration since stroke onset ranged from 1.4 to 84.9 months. The details regarding demographics, ESWT protocol, BoNT dosage, intervention sites, and duration of follow-up are presented in Tables 1 and 2.
Supplementary Fig. 2 presents the risk of bias graph. Since our meta-analysis only enrolled RCTs, most studies had a detailed description of their randomization procedure. The domains with the most failures were blinding of the participants/personnel or outcome assessment because some of the studies used a single-blind design.

### Comparison of WMDs (MAS scores before or at the 6th week after intervention)

In the pairwise meta-analysis (Fig. 2A), RSW, BoNT injections and FSW were significantly more effective than control treatments, with WMDs of -0.67 (95% CI, -0.80 to -0.55), -0.54 (95% CI, -0.57 to -0.50), and -0.34 (95% CI, -0.54 to -0.14), respectively. There were no significant differences when RSW was compared with FSW or BoNT injections.

The network graph is shown on Fig. 3A, disclosing the geometry of the treatment network. In the network meta-analysis (Fig. 4A), BoNT injections, FSW, and RSW were superior to the control treatment in reducing spasticity, with WMDs of -0.69 (95% CI, -0.87 to -0.50), -0.36 (-0.69 to -0.03), and -0.62 (95% CI, -0.84 to -0.40), respectively. No significant differences were observed when other treatment pairs were compared. The league tables for the pairwise and network meta-analyses are summarized in Supplemental Table 2. The loop inconsistency model (Supplementary Fig. 3A) did not reveal significant inconsistencies between direct and indirect comparisons.

In terms of treatment outcome before or at the 6th week post-intervention, the rank probability results and the value of SUCRA are presented in Fig. 5A and Table 3, respectively. RSW had the highest probability (62.2%) for being the best treatment, whereas BoNT injections had the highest probability (61.6%) to rank second-best. Furthermore, FSW and the control treatment were likely to be the third-best (98.1%) and the worst (99.9%) treatments, respectively.

### Comparison of WMDs (MAS scores between the 7th and 12th weeks)

In the pairwise meta-analysis (Fig. 2B), RSW, BoNT injections, and FSW were significantly superior to control treatments, with WMDs of -1.19 (95% CI, -1.29 to -1.09), -0.26 (95% CI, -0.29 to -0.23), and -0.70 (95% CI, -1.14 to -0.26), respectively. No significant differences were found in the comparisons of RSW vs. FSW and RSW vs. BoNT injections.

The network graph is shown on Fig. 3B, disclosing the geometry of the treatment network. In the network meta-analysis (Fig. 4B), BoNT injections, FSW, and RSW appeared to be significantly better than the control treatment, with WMDs of -0.44 (95% CI, -0.62 to -0.26), -0.74 (95% CI, -1.26 to -0.23), and -0.79 (-1.07 to -0.51), respectively. The effectiveness of RSW was superior to that of BoNT injections (WMD, -0.35; 95% CI, -0.65 to -0.04). No significant differences were observed when the other treatment pairs were compared. The league tables for the pairwise and network meta-analyses are summarized in Supplemental Table 3. The loop inconsistency models (Supplementary Fig. 3B) showed no significant inconsistencies between the direct and indirect comparisons.
Figure 2. Forest plots of pairwise comparison in terms of MAS reduction (A) before or at the 6th week after intervention and (B) between the 7th and 12th weeks after interventions. WMD, weighted mean difference. CI, confidence interval represents the mean treatment effect. FSW, focused shockwave; RSW, radial shockwave; MAS, modified Ashworth scale. APMR, Archives of Physical Medicine and Rehabilitation; BoNT, botulinum toxin; CMRO, current medical research and opinion; EJPRM, European Journal of Physical and Rehabilitation Medicine.
Regarding the reduction in the MAS between the 7th and 12th weeks, the rank probability results and the value of SUCRA are presented in Figure 5B and Table 3, respectively. The simulation of rank probabilities demonstrated that RSW had the highest probability (72.3%) to be the best treatment, followed by FSW as the second-best (72.0%). BoNT injections and the control treatment were likely to be the third-best (99.7%) and worst treatments (100.0%), respectively.

Publication bias
The funnel plots did not show obvious asymmetry in the intergroup comparisons of WMDs before or at the 6th week and between the 7th and 12th weeks (Supplementary Fig. 4). The p values of Egger’s test for the effect sizes before or at the 6th week and those between the 7th and 12th weeks were 0.048 and 0.183, respectively.

Discussion
The present meta-analysis explored the comparative effectiveness of BoNT injections vs. ESWT in the management of post-stroke spasticity using evidence from RCTs. The results indicated that BoNT injections, FSW, and RSW were all effective in alleviating spasticity for at least 12 weeks in comparison to control treatments. RSW was likely to have the best anti-spasticity effect among the three treatments included in this analysis.

Our results revealed attenuation of the anti-spasticity efficacy of BoNT injections in contrast to ESWT during mid-term follow-up. The effectiveness of BoNT injections has been well studied, showing a decline at six to eight weeks after administration. Among the reviewed articles, abobotulinumtoxinA was the most commonly used formulation, followed by onabotulinumtoxinA and incobotulinumtoxinA. However, the doses of BoNT administered to each muscle group varied significantly. Two antecedent studies confirmed a dose-response relationship, revealing a better anti-spasticity outcome with the use of higher BoNT doses per target muscle. We found that a study employed minimal doses (e.g., onabotulinumtoxinA 15 U and 7.5 U for flexor carpi ulnaris and flexor digitorum superficialis muscles, respectively) which were much lower than recent recommendations. Moreover, the injection protocols varied across the enrolled studies, comprising differences in the types of BoNT, targeted muscles groups, dosage of BoNT and the timing of injections after the onset of stroke (Table 2). The spastic muscles were injected with a standard dose per muscle in most of the trials, while five trials allowed the physicians to decide about the injection dose per muscle within a given range, and one trial allowed physicians to choose the targeted muscles for BoNT injections. Care should be taken since heterogeneity in the doses and regimens could lead to the lack of superiority of BoNT injections over ESWT as far as the reduction in mid-term spasticity is concerned.

Muscle hypertonia develops as a result of impaired reflexes and secondary changes in rheological muscle properties, such as fibrosis, stiffness, and atrophy. One previous study revealed no significant changes in the neurophysiological parameters (e.g., F-wave response and H-reflex to the maximum M-response ratio) after the application of ESWT. Comparing the effectiveness of ESWT applied to the myotendinous junction and the muscle belly using ultrasound guidance, Yoon et al. found no significant differences between the effectiveness at each of the two sites, regardless of the density of motor points. These findings indicate that ESWT plays no role in the alteration of spinal excitability or neuromuscular blockade. Modification of non-neurological factors, such as the elastic and viscous properties of the muscles, has been proposed as a mechanism for spasticity reduction.
Figure 4. Forest plots of network comparisons in terms of MAS reduction (A) before or at the 6th week after intervention and (B) between the 7th and 12th weeks after interventions. CI, confidence interval represents the mean treatment effect. BoNT, botulinum toxin; FSW, focused shockwave; RSW, radial shockwave; MAS, modified Ashworth scale.
Figure 5. Ranking probabilities for different treatment options in terms of MAS reduction (A) before or at the 6th week after intervention and (B) between the 7th and 12th weeks after interventions. BoNT, botulinum toxin; FSW, focused shockwave; RSW, radial shockwave; MAS, modified Ashworth scale.
Increased production of nitric oxide (a neurotransmitter prompting muscle relaxation), stimulation of the muscle spindle, and recovery of muscle extensibility may contribute to the decrease in hypertonic muscle tension after the use of ESWT. In our meta-analysis, most of the enrolled patients had chronic stroke and their affected limbs were speculated to have developed changes in muscular properties. The direct effect of ESWT on the spastic muscles might also contribute to its better efficiency (than BoNT injections) which heavily relies on neuromuscular junction conditions.

In the present meta-analysis, we found that RSW was superior to FSW in terms of anti-spasticity efficacy. The maximal energy of FSW on the tissue is limited to a certain depth, leading to a smaller targeted area than that obtained with RSW. Furthermore, if the depth for FSW is set at a region where the muscle is fibrotic, the anti-spasticity effects are expected to be poor. In contrast, the energy generated in RSW disperses through the spastic muscle, and the muscle volume covered by RSW is greater than that covered by FSW. Moreover, the striking of the metal projectile in RSW results in a stronger vibration effect than in FSW. The vibration of shockwaves can potentially improve the tension of targeted muscle by breaking the link between actin and myosin.

Energy flux density and dosage of ESWT varied significantly among the included trials. Because the primary purpose of this meta-analysis was to compare the effectiveness of BoNT injections and the different modes of ESWT; the influences of treatment sessions, targeted muscles and ESWT machine settings were beyond the scope of this study. In a review of nine studies, Oh et al. reported that differences in the number of ESWT shocks and application sites (e.g., upper vs. lower limbs) had a negligible influence on the anti-spasticity effect. Therefore, we believe that the heterogeneity across the ESWT protocols had little impact on the comparability of ESWT with other treatments in our network comparisons.

Regarding the safety of ESWT and BoNT injections, the enrolled studies did not report severe adverse effects. However, the major concern for BoNT injections is the formation of neutralizing antibodies (ranging from 0 to 3.6 %) after repeated treatments, which may jeopardize its therapeutic effects. Alteration of muscle mechanics and intramuscular connective tissue contents were observed in the rat model following BoNT injections. Unintended botulism-like syndrome is possible when hematogenic systemic spread occurs, particularly using a high injection dose. On the contrary, the side effects of ESWT are usually mild, encompassing skin petechial or transient localized pain.

With regard to the effectiveness of BoNT injections, studies probing BoNT injections appeared to be more numerous than those using FSW or RSW. The effectiveness and safety of BoNT injections for spasticity reduction have been investigated in more details than those of ESWT. Furthermore, there was only one therapeutic arm with head-to-head comparison between ESWT and BoNT injections. The majority of BoNT injection vs. ESWT comparisons were derived from indirect comparisons performed through control treatments. Therefore, based on our meta-analysis, although the effectiveness of ESWT seemed comparable to BoNT injections, more RCTs directly comparing BoNT injections and ESWT are needed to confirm our preliminary observations.

The present study had some limitations. First, MAS (the most widely used method for spasticity assessment) was chosen as the main outcome. Our meta-analysis did not include studies using other assessment tools (e.g., the Tardieu scale) because of concerns regarding comparability. However, in the pertinent literature, there are only a few trials that have used non-MAS scales for spasticity evaluation; therefore, this would have had a minimal impact on our results. Herewith, Modified Ashworth Scale (MMAS) can be considered for spasticity assessment in future studies due to better reliability. Second, to facilitate the analysis, we treated MAS as a continuous variable. Accordingly, the pooled mean differences derived from our analysis could only be used to represent the direction and association between the treatment and its effect, but they might be insufficient to reflect the true effectiveness of the treatment. Third, long-term outcomes are lacking in our meta-analysis. The majority of the enrolled trials only followed patients for up to three months. As such, whether the effectiveness of BoNT injections and ESWT...
persists after the post-treatment third month requires further investigation. Fourth, the control groups included various therapies, including placebo injection, oral medication, and physical therapy. This may have caused high uncertainty, expressed by an enlarged 95% CI of the effect size in the control treatment. However, the effectiveness of the control groups was not our primary focus of investigation, and we believe that the intra-group heterogeneity would have a low influence on the interpretation of comparisons between BoNT injections and ESWT. Fifth, although previous studies reported insignificant influence on the anti-spasticity effects of ESWT regarding the amount of shock impulses per session and the application sites, the number of muscles needed to be treated could be another issue worth further investigation.

In conclusion, BoNT injections and ESWT are effective in alleviating post-stroke spasticity for at least 12 weeks. The effectiveness of ESWT was comparable to that of BoNT injections, whereas our meta-analysis indicated that RSW had the best potential among the three therapeutic options. More prospective trials incorporating head-to-head comparisons of BoNT injections vs. ESWT are needed to consolidate the use of ESWT for treating spasticity in chronic stroke.

Author Contributions
P.C.H. and K.V.C had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: P.C.H., K.V.C. and Y.H.C.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: P.C.H.
Critical revision of the manuscript for important intellectual content: K.V.C. and L.O.
Statistical analysis: P.C.H. and W.T.W
Obtained funding: K.V.C
Administrative, technical, or material support: K.V. and Y.H.C.
Supervision: L.O.

Declaration of Competing Interest
Each author certifies that he or she has no commercial associations
Funding
The current research project was supported by (1) National Taiwan University Hospital, Bei-Hu Branch; (2) Ministry of Science and Technology (MOST 106-2314-B-002-118-MY3 and 109-2314-B-002-114-MY3); 3) Taiwan Society of Ultrasound in Medicine.

Data sharing statement
All data of the current study would be available upon reasonable request to the corresponding author.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi:10.1016/j.eclinm.2021.101222.

References
1. Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology 1982;30(2):1703–15.
2. Trompetto C, Marinelli I, Mori L, et al. Pathophysiology of spasticity: implications for neurorehabilitation. Biomed Res Int 2014;2014:3549056.
3. Sommerfeldt DK, Eek EU, Svensson AS, Holmqist LW, von Ahn MH. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004;35(6):1549–54.
4. Ward AB. A literature review of therapeutic options and onset of post-stroke spasticity. Eur J Neurol 2012;19(3):21–7.
5. Bethoux F. Spasticity Management After Stroke. Phys Med Rehabil Clin N Am 2015;26(4):625–39.
6. Ghai A, Garg N, Hooda S, Gupta T. Spasticity - Pathogenesis, prevention and treatment strategies. Saudi J Anaesth 2017;11(4):453–60.
7. Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, Mozaffar T. A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Critical Reviews in Physical and Rehabilitation Medicine 2015;25(1-2):31–22.
8. Anwar F, Ramanaithan S, Khayer A. Complications of Peripheral Phenol Nerve and Motor Point Blocks in the Management of Spasticity. International Journal of Therapies and Rehabilitation Research 2017;6(2).
9. Andringa A, van de Port I, van Wegen E, Ket J, Meskers C, Kwakkel G. Effectiveness of Botulinum Toxin Treatment for Upper Limb Spasticity Poststroke Over Different ICF Domains: A Systematic Review and Meta-Analysis. Archives of physical medicine and rehabilitation 2019;100(3):1703–25.
10. Roberts A. Surgical management of spasticity. J Child Orthop 2013;7(5):89–94.
11. Walewicz K, Taradaj J, Rajfur K, et al. The Effectiveness Of Radial Extracorporeal Shock Wave Therapy In Patients With Chronic Lower Back Pain: A Prospective, Randomized, Single-Blinded Pilot Study. Clin Interv Aging 2019;14:859–69.
12. Gao J, Rubin JM, Chen J, O’Dell M. Ultrasound Elastography to Assess Botulinum Toxin A Treatment for Poststroke Spasticity: A Feasibility Study. Ultrasound Med Biol 2019;45(5):1054–62.
13. Stecco A, Stecco C, Raghavan P. Peripheral Mechanisms Contributing to Spasticity and Implications for Treatment. Current Physical Medicine and Rehabilitation Reports 2014;2(2):122–7.
14. El-Shamy SM, Eid MA, El-Banna MF. Effect of extracorporeal shock wave therapy on gait pattern in hemiplegic cerebral palsy: a randomized controlled trial. American journal of physical medicine & rehabilitation 2014;93(12):1055–72.
15. Martinez JM, Sempere-Rubio N, Navarro O, Faubel R. Effectiveness of Shock Wave Therapy as a Treatment for Spasticity: A Systematic Review. Brain Sci 2020;10(1).
16. Wu YT, Yu HK, Chen LR, Chang CN, Chen YM, Hu GC. Extracorporeal Shock Waves Versus Botulinum Toxin Type A in the Treatment of Poststroke Upper Limb Spasticity: A Randomized Noninferiority Trial. Archives of physical medicine and rehabilitation 2018;99(1):214–30.
17. Cabanas-Valdes R, Serra-Llobet G, Casas-Flores C, Lopez-de-Celis C, Llaurado-Foles M, Calvo-Sanz J. The effectiveness of extracorporeal shock wave therapy for improving upper limb spasticity and functionality in stroke patients: a systematic review and meta-analysis. Clin Rehabil 2020;34(1):114–6.
18. Cabanas-Valdes R, Calvo-Sanz J, Urrutia G, Serra-Llobet P, Perez-Bellmunt A, German-Romero A. The effectiveness of extracorporeal shock wave therapy to reduce lower limb spasticity in stroke patients: a systematic review and meta-analysis. Top Stroke Rehabil 2020;27(2):117–57.
19. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162(11):777–84.
20. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
21. Dressler D, Benez E. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 2007;29(13):1761–8.
34 Taheri P, Vahdatpour B, Mellat M, Ashtari F, Akbari M. Effect of radial shock wave therapy on spasticity in stroke patients. J Korean Acad Rehabil Med 2010;34:605–9.

35 Duan HY, Li XL, Xu FQ, Liu FQ, ZHY. Efficacy of extracorporeal shock wave treatment in the treatment of spasticity of biceps brachii in stroke patients. Journal of Jilin University Medicine Edition 2010;46(6):663–9.

36 Wu YT, Chang CN, Chen YM, Hu GC. Comparison of the effect of focused and radial extracorporeal shock waves on spastic equinus in patients with stroke: a randomized controlled trial. Eur J Phys Rehabil Med 2018;54(4):318–25.

37 Xu G, Yan Z, Zhang Y, et al. Therapeutic effect of slow stretching training combined with extracorporeal shock wave on biceps brachii spasticity in patients with stroke. Journal of Jilin University Medicine Edition 2018;44(2):374–8.

38 Yoon SH, Shin MK, Chui EJ, Kang HJ. Effective Site for the Application of Extracorporeal Shock Wave Therapy on Spasticity in Chronic Stroke Patients: Muscle Belly or Mystenodinous Junction. Annals of rehabilitation medicine 2017;41(4):547–55.

39 Yoldas Aslan S, Kullay S, Dosimucu Ataman E, Elhan AH, Gok H, Kucukdeveci AA. Does extracorporeal shock wave therapy decrease spasticity of ankle plantar flexor muscles in patients with stroke: A randomized controlled trial. Clin Rehabil 2021;35:2131121011202.

40 Bakheit AM, Pittoc S, Moore AP, et al. Randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001;8(6):555–69.

41 Bakheit AM, Thulmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31(12):2402–6.

42 Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomized double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69(2):227–32.

43 Childress MK, Brashier A, Ioffe-Czyzyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper limb spasticity in patients after a stroke. Archives of physical medicine and rehabilitation 2004;85(1):1065–9.

44 Hesse S, Seiter F, Konrad M, Jahne MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil 1998;12(8):583–9.

45 Jalangir AW, Tan HJ, Norlinah MI, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. Med J Malaysia 2007;62(4):359–22.

46 Kaj R, Osako Y, Suyama K, et al. Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 2012;28(8):1081–9.

47 Kaj R, Osako Y, Suyama K, et al. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol 2010;257(8):1530–7.

48 Kerzoncuf M, Viton JM, Pellas F, et al. Poststroke Postural Sway Improved by Botulinum Toxin: A Multicenter Randomized Double-blind Controlled Trial. Archives of physical medicine and rehabilitation 2020;101(4):242–8.

49 Marciniak CM, Harvey RL, Gagnon CM, et al. Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity? A randomized, double-blind, placebo-controlled trial. American journal of physical medicine & rehabilitation 2012;91(12):1007–19.

50 Marco E, Durante E, Vila J, et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. Journal of rehabilitation medicine 2007;39(6):440–7.

51 Prasser A, Lira M, Aguer P, Montero L, Vilashois I, Melo A. Efficacy of physical therapy associated with botulinum toxin type A on functional performance in post-stroke spasticity: A randomized, double-blind, placebo-controlled trial. Neurol Int 2018;10(1):73–85.

52 Shaw L, Rodgers H, Price C, et al. BotULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess 2010;14(6):1–113, iii–iv.

53 Hesse S, Mach F, Hochrindl S, Behrend S, Werner C, Melzer I. An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: a randomized controlled trial. Clin Rehabil 2012;26(5):357–45.

54 McCorry P, Turner-Stokes L, Baguley JI, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other patient-centred outcomes. Journal of rehabilitation medicine 2020;52(7):550–44.

55 Rosales RL, Balcaitiene J, Berard H, et al. Early Abobotulinumtoxin-a (Dysport(R)) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study. Toxins (Basel) 2018;10(7).

56 Wolf SL, Milton SB, Reiss A, Easley KA,Shermi NV, Clark PC. Further assessment to determine the additive effect of botulinum toxin type A on an upper extremity exercise program to enhance function among individuals with chronic stroke but extensor capability. Archives of physical medicine and rehabilitation 2012;93(4):738–87.

57 Bensmail D, Hanschmann A, Wissel J. Satisfaction with botulinum toxin treatment in post-stroke patients after a stroke. J Neurol Neurosurg Psychiatry 2010;81(4):458–61.

58 Dressler D, Altavista MC, Altenmueller E, et al. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. J Neural Transm (Vienna) 2012;120(5):615–25.

59 Dietz V, Sinkjaer T. Spastic movement disorder: impaired reflex and neurogenic mechanisms in phase subaigu. A: base a control experiment. Kinesintherapie, la Revue 2015;46(2):185–71.

60 Gaverth J, Sandgren M, Lindberg PG, Forssberg H, Eliasson AC. Does extracorporeal shock wave therapy decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity? A randomized, double-blind, placebo-controlled trial. Complement Ther Clin Pract 2015;21(1):31–5.

61 Gaverth J, Sandgren M, Lindberg PG, Forssberg H, Eliasson AC. Does extracorporeal shock wave therapy decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity? A randomized, double-blind, placebo-controlled trial. Complement Ther Clin Pract 2015;21(1):31–5.
63 Amelio E, Manganotti P. Effect of shock wave stimulation on hypertonic plantar flexor muscles in patients with cerebral palsy: a placebo-controlled study. *Journal of rehabilitation medicine* 2010;42(4):339–45.
64 Gracies JM. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. *Muscle Nerve* 2005;31(5):535–51.
65 Altindag O, Gursoy S. Effect of Shock Wave Therapy on Spasticity: A Single-Institution Experience. *Türkiye Fizykal Tip ve Rehabilitasyon Dergisi* 2014;60(1):95–6.
66 Oh JH, Park HD, Han SH, Shim GY, Choi KY. Duration of Treatment Effect of Extracorporeal Shock Wave on Spasticity and Subgroup-Analysis According to Number of Shocks and Application Site: A Meta-Analysis. *Annals of rehabilitation medicine* 2019;43(2):163–77.
67 Bellows S, Jankovic J. Immunogenicity Associated with Botulinum Toxin Treatment. *Toxins (Basel)* 2019;11(9).
68 Kaya CS, Yilmaz EO, Akdeniz-Dogan ZD, Yucsesoy CA. Long-Term Effects With Potential Clinical Importance of Botulinum Toxin Type-A on Mechanics of Muscles Exposed. *Front Bioeng Biotechnol* 2020;8:338.
69 Tugnoli V, Eleopra R, Quattrale R, Capone JG, Sensi M, Gastaldo E. Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis. *Br J Dermatol* 2002;147(4):808–9.
70 Banky M, Ryan HK, Clark R, Olver J, Williams G. Do clinical tests of spasticity accurately reflect muscle function during walking: A systematic review. *Brain Inj* 2017;31(4):440–55.